By vgreene, 9 June, 2021 No significant difference in 28 day all cause mortality convalescent plasma 24 vs SOC 24 RR 1 95 CI 0 93 1 07 no significant difference in death rate invasive mech vent composite endpoint
By vgreene, 9 June, 2021 Hospitalized pts mean age 63 5y w suspected or confirmed COVID 19 randomized to convalescent plasma n 5 795 vs SOC only n 5 763 other tx incl CS 92 AZ 10 or colchicine 14 at randomization 5 received mech vent 87 needed O2 only
By vgreene, 9 June, 2021 Randomized controlled open label adaptive platform study current analysis incl convalescent plasma vs SOC only results for other tx arms forthcoming
By vgreene, 9 June, 2021 Study considerations randomized but open label incl limited numbers of peds pregnant and breastfeeding pts does not address benefits if convalescent plasma given earlier no evidence of differential effect due to B 1 1 7 variant
By vgreene, 9 June, 2021 Study considerations randomized but open label incl limited numbers of peds pregnant and breastfeeding pts does not address benefits if convalescent plasma given earlier no evidence of differential effect due to B 1 1 7 variant
By vgreene, 9 June, 2021 KEY FINDINGS convalescent plasma did not improve survival or other prespecified clinical outcomes
By vgreene, 9 June, 2021 Convalescent Plasma in Patients Admitted to Hospital With COVID 19 RECOVERY A Randomised Controlled Open label Platform Trial
By vgreene, 9 June, 2021 Death or hospital admission not significantly less w colchine vs placebo 4 7 vs 5 8 OR 0 79 CI 0 61 1 03 in subgroup of pts w PCR confirmed dx death or hospital admission significantly less in colchicine group 4 6 vs 6 3 OR 0 75 CI 0 57 0 99 diarrhea repo
By vgreene, 9 June, 2021 Multicenter double blind adaptive RCT non hospitalized pts median 54y w at 1 high risk factor received colchicine 0 5 mg PO bid x3 days then 0 5 mg PO qd x27 days n 2 235 or placebo n 2 253
